Pharmacogenetics strategies: From candidate genes to whole-genome association analysis. Exploratory or confirmatory studies?

Current Pharmacogenomics and Personalized Medicine

Volumn 7 1, Issue , 2009, Pages 59-69

  Mas, S ^a   Lafuente, Amalia ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADDUCIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSINOGEN; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COUMARIN DERIVATIVE; CYTOCHROME P450 2C9; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLIBENCLAMIDE; GLIMEPIRIDE; GLYCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RENIN; SALICYLIC ACID; TOLBUTAMIDE; TRYPTOPHAN; WARFARIN; COUMARIN;

ANTICOAGULATION; CLINICAL PRACTICE; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER PROGRAM; DISEASE PREDISPOSITION; DRUG RESPONSE; DRUG TRANSFORMATION; EXPLORATORY RESEARCH; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE MAP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INDIVIDUALIZATION; INTERMETHOD COMPARISON; KNOWLEDGE BASE; MEDICAL LITERATURE; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT PARTICIPATION; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; POLYMERASE CHAIN REACTION; RESEARCH SUBJECT; REVIEW; SAMPLE SIZE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; TREATMENT OUTCOME; DIABETES MELLITUS; DRUG MECHANISM; GENETIC RISK; GENOME ANALYSIS; WHOLE GENOME ASSOCIATION ANALYSIS;

EID: 70249083839     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569209787582367     Document Type: Review

References (54)

1. Arnett, D. K.; Boerwinkle, E.; Davis, B. R.; Eckfeldt, J.; Ford, C. E. and Black, H. (2002) Pharmacogenetic approaches to hypertension therapy; design and rationale for the genetics of Hypertension Associate (GenHAT) study. Pharmacogenomics J. 2, 309-317.
2. Balding, D. J. (2006) A tutorial on statistical methods for population association studies. Nat. Rev. 7, 781-791.
3. Barret, J. C.; Fry, B.; Moller, J. and Daily, M. J. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265.
4. Becker, M. L.; Visser, L. E.; Trienekens, P. H.; Hofman, A.; van Schik, R. H. N. and Stricker, B. H. C. (2008) Cytochrome P450 2C9*2 and *3 polymorphisms and dose and effect of sulfonylurea in type II Diabetes Mellitus. Clin. Pharmacol. Ther. 83, 288-292.
5. Bleumink, G. S.; Schut, A. F. C.; Sturkenboom, M. C. J. M.; van Duijn, C. M.; Deckers, J. W.; Hofman, A.; Kingma, J. H.; Witteman, J. C. M.; Stricker, B. H. Ch. and Bruno, H. (2005) Mortality in patients with hypertension on angiotensin-I converting enzyme (ACE)-inhibitor treatment is influenced by the ACE insertion/deletion polymorphism. Pharmacogen. Genomics 15, 75-81.
6. Bodin, L.; Verstuyft, C.; Tregouet, D. A.; Robert, A.; Dubert, L. and Funck-Brentano, C. (2005) Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants ofacenocoumarol sensitivity. Blood 106, 135-140.
7. Braff, D. L.; Freedman, R.; Schork, N. J. and Gottesman, I. I. (2007) Deconstructing schizophrenia; an overview of the use of endophenotypes in order to understand a complex disease. Schizophrenia Bull. 33, 21-32.
8. Consortium I. H. A. (2005) A haplotype map of the Human Genome. Nature 437, 1299-1320.
9. Court, M. H. A. (2007) A pharmacogenomics primer. J. Clin. Pharmacol. 47, 1087-1113.
10. Crescenti, A.; Mas, S.; Gasso, P.; Baiget, M.; Bernardo, M. and Lafuente, A. (2007) Simultaneous genotyping of CYP2D6*3,*4,*5 and *6 polymorphisms in a Spanish population through multiplex long-PCR and minisequencing multiplex Single Base Extension (SBE) Analysis. Clin. Exp. Pharmacol. Psysiol. 34, 992-997.
11. Crespi, C. L. and Miller, V. P. (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics. 7, 203-210.
12. Davis, B. R.; Arnett, D. K.; Boerwinkle, E.; Ford, C. E.; Leiendecker-Foster, C.; Miller, M. B.; Black, H. and Eckfeldt, J. H. (2007) Antihypertensive therapy, the α-adducin polymorphisms and cardiovascular disease in high-risk hypertensive persons. Pharmacogenomics J. 7, 112-122.
13. Dehgan, A.; Kardys, I.; de Maat, M. P. M.; Vitterlinden, A. G.; Sijbrands, E. J. G.; Bootsma, A. H.; Stijnen, T.; Hofman, A.; Schram, M. T. and Witteman, J. C. M. (2007) Genetic variation, c-reactive protein levels and incidence of diabetes. Diabetes 56, 872-878.
14. Dudbridge, F. UNPHASED user guide. Technical report 2006/5, MRC Biostatistics Unit, Cambridge, UK.
15. Grant, S. F. and Hakonarson, H. (2007) Recent development in pharmacogenomics: from candidate genes to genome-wide association studies. Expert Rev. Mol. Diagn. 7, 371-393.
16. Gunderson, K. L.; Kuhn, K. M.; Steeners, F. J.; Ng, P.; Murray, S. S. and Shen, R. (2006) Whole genome genotyping og haplotype tagg single nucleotide polymorphisms. Pharmacogenomics J. 7, 641-648.
17. Haining, R. L.; Hunter, A. P.; Veronese, M. E.; Trager, W. F. and Rettie, A. E. (1996) Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch. Biochem. Biophys. 333, 447-458.
18. Hernandez-Boussard, T.; Woom, M.; Klein, T. E. and Altman, R. B. (2006) Integrating large-scale genotype and phenotype data. OMICS 10, 545-550.
19. Hinds, D. A.; Seymour, A. B.; Durham, L. K.; Banerjee, P.; Ballinger, D. G.; Milos, P. M.; Cox, D. R.; Thompson, J. F. and Frazer, K. A. (2004) Application of pooled genotyping to scan candidate regions for association with HDL cholesterol levels. Hum. Genomics 6, 421-434.
20. Hofman, A.; Grobbee, D. E.; de Jong, P. T. and van den Ouweland, F. A. (1991) Determinants of disease and disability in the elderly; the Rotterdam elderly study. Eur. J. Epidemiol. 7, 403-422.
21. John, S.; Shephard, N.; Liu, G.; Zeggini, E.; Cao, M.; Chen, W.; Vasavda, N.; Mills, T.; Barton, A.; Hinks, A.; Eyre, S.; Jones, K. W.; Ollier, W.; Silman, A.; Gibson, N.; Worthington, J. and Kennedy, G. C. (2004) Whole-genome scan, in a complex disease, using 11,245 single-nucleotide polymorphisms: comparison with microsatellites. Am. J. Hum. Genet. 75, 54-64.
22. Kimura, R.; Miyashida, K.; Kokubo, Y.; Akaiwa, Y.; Otsubo, R. and Nagatsuka, K. (2007) Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb. Res. 120, 181-186
23. Koed, K.; Wiuf, C.; Christensen, L. L.; Wikman, F. P.; Zieger, K.; Møller, K.; von der Maase, H. and Orntoft, T. F. (2005) High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res. 65, 34-45.
24. Lumm, D. J.; Whittaker, J. C. and Best, N. (2006) Bayesian toolkit for genetic association studies. Genet. Epidemiol. 30, 231-247.
25. Mas, S.; Crescenti, A.; Gassó, P.; Vidal-Taboada, J. M. and Lafuente, A. (2007) DNA cards: Determinants of DNA yield and quality in collecting genetic samples for pharmacogenetic studies. Basic Clin. Pharmacol. Toxicol. 101, 132-137.
26. Mas, S.; Crescenti, A.; Vidal-Taboada, J. M.; Bergonon, S.; Cuevillas, F.; Laso, N. and Lafuente, A. (2005) Simultaneous genotyping of CYP2C9*2, *3, and 5′ flanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extension analysis. Eur. J. Clin. Pharmacol. 61, 635-641.
27. Nebert, D. W.; Zhang, G. and Vesell, E. S. (2008) From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab. Rev. 40, 187-224.
28. Pinkel, D. and Albertson, D. G. (2005) Array comparative genomic hybridization and its application in cancer. Nat. Genet. 37, 11-17.
29. Reitsma, P. H.; van der Heijden, J. F.; Groot, A. P.; Rosendaal, F. R. and Buller, H. R. (2005) A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med. 2, e312.
30. Rettie, A. E.; Wienkers, L. C.; Gonzalez, F. J.; Trager, W. F. and Korzekwa, K. R. (1994) Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant ofCYP2C9. Pharmacogenetics 4, 39-42.
31. Rieder, M. J.; Reiner, A. P.; Gage, B. F.; Nickerson, D. A.; Eby, C. S. and McLeod, H. L. (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293.
32. Rost, S.; Fregin, A.; Ivaskevicius, V.; Conzelmann, E.; Hortnagel, K. and Pelz, H. J. (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537-541.
33. Saba, T. G.; Montpetit, A.; Verner, A.; Rioux, P.; Hudson, T. J.; Drouin, R. and Drouin, C. A. (2005) An atypical form of erythrokeratodermia variabilis maps to chromosome 7q22. Hum. Genet. 116, 167-71.
34. Sabbati, C. (2007) Avoiding false discoveries in association studies. Methods Mol. Biol. 376, 195-211.
35. Sanderson, S.; Emery, J. and Higgins, J. (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet. Med. 7, 97-104.
36. Schaid, D. J.; Guenther, J. C.; Christensen, G. B.; Hebbring, S.; Rosenow, C.; Hilker, C. A.; McDonnell, S. K.; Cunningham, J. M.; Slager, S. L.; Blute, M. L. and Thibodeau, S. N. (2004) Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility Loci. Am. J. Hum. Genet. 75, 948-965.
37. Schelleman, H.; Klungel, O. H.; Witteman, J. C. M.; Breteler, M. M. B.; Yazdanpanah, M.; Danser, A. H. J.; Hofman, A.; van Duijn, C. M.; de Boer, A. and Stricker, B. H. C. (2007) Angiotensinogen M235T polymorphism and the risk of miocardial infarction and stroke among hypertensive patients on ACE-inhibitors or β-blockers. Eur. J. Hum. Genet. 15, 478-484.
38. Sconce, E. A.; Khan, T. I.; Wynne, H. A.; Avery, P.; Monkhouse, L. and King, B. P. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333.
39. Segal, E.; Friedman, N.; Kaminski, N.; Reger, A. and Koller, D. (2005) From signatures to models: understanding cancer with microarrays. Nat. Genet. 37, 38-45.
40. Sigurdsson, S.; Nordmark, G.; Göring, H. H.; Lindroos, K.; Wiman, A. C.; Sturfelt, G.; Jönsen, A.; Rantapää-Dahlqvist, S.; Möller, B.; Kere, J.; Koskenmies, S.; Widén, E.; Eloranta, M. L.; Julkunen, H.; Kristjansdottir, H.; Steinsson, K.; Alm, G.; Rönnblom, L. and Syvänen, A. C. (2005) Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 76, 528-537.
41. Syvänen, A. C. (2005) Toward genome-wide genotyping. Nat. Genet. 37, 555-510.
42. The Post Coronary Artery Bypass Graft Trial Investigators. (1997) The effect of aggressive lowering low-density lipoprotein cholesterol levels and low-dose anticuagulation on obstructive changes in saphenous vein coronary artery bypass graft. N. Engl. J. Med. 336, 153-162.
43. Thompson, J. F.; Man, M.; Johnson, K. J.; Woods, L. S.; Lira, M. E.; Lloyd, D. B.; Banergee, P.; Milos, P. M.; Myrand, S. P.; Paulasuskis, J.; Miland, M. A. and Sasiela, W. J. (2005) An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 5, 352-358.
44. van Rijn, M. J. E.; Bog, M. J.; Isaacs, A.; Yazdanpanah, M.; Stricker, B. H. C.; Klungel, O. H.; Oostra, B. A.; Koudstaal, P. J.; Witteman, J. C. M.; Hofman, A.; Breteler, M. M. B. and van Duijn, C. M. (2007) Polymorphisms of the renin-angiotensin system are associted with blood pressure, atherosclerosis and cerebral white matter pathology. J. Neurol. Neurosurg. Psychiatry 78, 1083-1087.
45. Veenstra, D. L.; You, J. H.; Rieder, M. J.; Farin, F. M.; Wilkerson, H. W. and Blough, D. K. (2005) Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics 15, 687-691.
46. Vidal-Taboada, J. M.; Cucala, M.; Mas, S.; Lafuente, A. and Cobos, A. (2006) Satisfaction survey with DNA cards method to collect genetic sample for pharmacogenetic studies. BMC Med. Genet. 7, 45.
47. Visser, L. E.; Trienekens, P. H.; De Smet, P. A.; Vulto, A. G.; Hofman, A.; van Duijn, C. M. and Stricker, B. H. Ch. (2005) Patients with an ApoE ε4 allele require lower doses of coumarin anticoagulants. Pharmacogenet. Genomics 15, 69-74.
48. Visser, L. E.; van Vliet, M.; van Schaik, R. H. N.; Kasbergen, A. A. H.; De Smet, P. A. G. M; Vulto, A. G.; Hofman, A.; van Duijn, C. M. and Stricker, B. H. Ch. (2004) The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 14, 27-33.
49. Wadelius, M.; Chen, L. Y.; Downes, K.; Ghori, J.; Hunt, S. and Eriksson, N. (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270.
50. Wadelius, M. and Pirmohamed, M. (2007) Pharmacogenetics of warfarin; current status and future challenges. Pharmacogenomics J. 7, 99-111.
51. Yin, T. and Miyata, T. (2007) Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1-rationale and perspectives. Thromb. Res. 120, 1-10.
52. Yuan, H. Y.; Chen, J. J.; Lee, M. T.; Wung, J. C.; Chen, Y. F. and Charng, M. J. (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14, 1745-1751.
53. Zhao, J. H. and Tan, Q. (2006) Integrated analysis of genetic data with R. Hum. Genomics 2, 258-265.
54. Zhao, X.; Li, C.; Paez, J. G.; Chin, K.; Jänne, P. A.; Chen, T. H.; Girard, L.; Minna, J.; Christiani, D.; Leo, C.; Gray, J. W.; Sellers, W. R. and Meyerson, M. (2004) An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res. 64, 3060-3071.